Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
RLMD vs PLUR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RLMD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)
RLMD Overall Winner
6-Pillar Tally: RLMD 4 – 1 PLUR (1 Tie)
Matrix Metrics: RLMD 5 – 4 PLUR
As of Nov 17, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RLMD carries a Unified Composite Score of 39.0/100 (SELL) at $3.00 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).
- Defensive Composite Rating Caution: Although RLMD compares more favorably head-to-head, both RLMD (39.0/100 SELL) and PLUR (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RLMD vs PLUR
RLMD
Head-to-Head Winner
Relmada Therapeutics, Inc. Common Stock
$3.00
-16.76% 1D
Market Cap
$449.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.69β · 107% Vol
Unified Composite Score
39.0
SELL
Tech 15.0
Fund 38.0
Flow 68.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
PLUR
Pluri Inc.
$0.94
-9.19% 1D
Market Cap
$15.1M
TTM Revenue
$1.0M
Forward P/E
3.6x
Beta / 30D Vol
0.80β · 102% Vol
Unified Composite Score
28.8
SELL
Tech 15.0
Fund 34.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (RLMD 4 – 1 PLUR)
1. Valuation Multiples
PLUR
Forward P/E
N/M
3.6x
Trailing P/E
N/M
3.6x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
44.6x
2. Growth & Scale
RLMD
Revenue Growth (YoY)
+0.0%
-15.8%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$1.0M
Market Cap
$449.2M
$15.1M
3. Profitability & Quality
RLMD
Gross Margin
N/A
44.6%
Operating Margin
0.0%
-2454.5%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-64.7%
-1022.0%
4. Balance Sheet & Cash Flow
RLMD
Cash Generation (TTM)
-$46M
-$22M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.82 Book/Sh · -64.7% ROE
$30M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RLMD
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
93.2% (36th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RLMD (5) vs PLUR (4)| Institutional Metric | RLMD | PLUR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $449.2M | $15.1M | RLMD | |
| Trailing P/E Ratio | N/M | 3.6x | PLUR | |
| Forward P/E Ratio | N/M | 3.6x | PLUR | |
| Revenue Growth (YoY) | +0.0% | -15.8% | RLMD | |
| Operating Margin (TTM) | 0.0% | -2454.5% | RLMD | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -64.7% | -1022.0% | RLMD | |
| 52-Week Range Position | 0% ($3–$8) | 2% ($1–$5) | PLUR | |
| Beta / 30D Volatility | 1.69β · 107% Vol | 0.80β · 102% Vol | PLUR | |
| Unified Institutional Score | 39.0 / 100 (SELL) | 28.8 / 100 (SELL) | RLMD | |
| Trailing 12M Revenue (USD) | N/A | $1.0M | Scale | |
| Gross Profit Margin (TTM) | N/A | 44.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 44.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$46M ($1.82 Book/Sh · -64.7% ROE) | -$22M ($30M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PLUR +16.0 pp
3M Horizon
RLMD +8.56 pp
6M Horizon
RLMD +5.27 pp
1Y Horizon
RLMD +51.61 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RLMD Revenue | PLUR Revenue | RLMD Op. Margin | PLUR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -67462.0% | PLUR |
| FY2019 | N/A | $0M | N/A | -65800.0% | PLUR |
| FY2020 | N/A | $0M | N/A | -128156.5% | PLUR |
| FY2022 | N/A | $0M | N/A | -17774.8% | PLUR |
| FY2023 | N/A | $0M | N/A | -9493.4% | PLUR |
| FY2024 | N/A | $0M | N/A | -6796.9% | PLUR |
| FY2025 | N/A | $0M | N/A | -1659.9% | PLUR |
| FY2026 | N/A | $0M | N/A | -2454.5% | PLUR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RLMD
BREAKDOWN
Current IV
93.2%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RLMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PLUR
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RLMD Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PLUR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ RLMD vs PLUR Key Questions & Quantitative Answers
As of Nov 17, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RLMD carries a Unified Composite Score of 39.0/100 (SELL) at $3.00 (N/M Forward P/E, 0.0% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Defensive Composite Rating Caution: Although RLMD compares more favorably head-to-head, both RLMD (39.0/100 SELL) and PLUR (28.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RLMD leads the Growth & Scale pillar: RLMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), RLMD cumulative revenue shifted N/A while PLUR shifted N/A. In operating R&D and SG&A reinvestment, RLMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.
PLUR screens cheaper on headline valuation multiples. RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLMD (-64.7% ROE) versus PLUR (-1022.0% ROE) capital efficiency.
In options market volatility and institutional positioning, RLMD carries 93.2% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 107% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PLUR vs RLMD · Reverse Pair
RLMD vs STOK
· Sector Peer
RLMD vs FULC
· Sector Peer
RLMD vs PHAT
· Sector Peer
PLUR vs SRZN
· Sector Peer
PLUR vs PYPD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem